Net Income (Loss) Attributable to Parent in USD of Nuo Therapeutics, Inc. from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Nuo Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q2 2010 to Q3 2025.
  • Nuo Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$537,919.000, a 6.96% increase year-over-year.
  • Nuo Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$2,430,402.000, a 2.01% increase year-over-year.
  • Nuo Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$2,323,705.000, a 26.7% increase from 2023.
  • Nuo Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$3,171,436.000, a 0.01% increase from 2022.
  • Nuo Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$3,171,736.000, a 3398% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Nuo Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$2,430,402 -$537,919 +$40,248 +7% 01 Jul 2025 30 Sep 2025 10-Q 30 Oct 2025
Q2 2025 -$2,470,650 -$649,689 -$109,598 -20.3% 01 Apr 2025 30 Jun 2025 10-Q 30 Oct 2025
Q1 2025 -$2,361,052 -$746,128 -$37,347 -5.3% 01 Jan 2025 31 Mar 2025 10-Q 30 Oct 2025
Q4 2024 -$2,323,705 -$496,666 +$156,489 +24% 01 Oct 2024 31 Dec 2024 10-K 01 Apr 2025
Q3 2024 -$2,480,194 -$578,167 +$212,473 +26.9% 01 Jul 2024 30 Sep 2024 10-Q 30 Oct 2025
Q2 2024 -$2,692,667 -$540,091 +$331,795 +38.1% 01 Apr 2024 30 Jun 2024 10-Q 30 Oct 2025
Q1 2024 -$3,024,462 -$708,781 +$146,974 +17.2% 01 Jan 2024 31 Mar 2024 10-Q 30 Oct 2025
Q4 2023 -$3,171,436 -$653,155 +$306,362 +31.9% 01 Oct 2023 31 Dec 2023 10-K 01 Apr 2025
Q3 2023 -$3,477,798 -$790,640 +$122,149 +13.4% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024
Q2 2023 -$3,599,947 -$871,886 +$52,164 +5.6% 01 Apr 2023 30 Jun 2023 10-Q 12 Nov 2024
Q1 2023 -$3,652,111 -$855,755 -$480,375 -1.3% 01 Jan 2023 31 Mar 2023 10-Q 12 Nov 2024
Q4 2022 -$3,171,736 -$959,517 -$887,865 -12.4% 01 Oct 2022 31 Dec 2022 10-K 19 Apr 2024
Q3 2022 -$2,283,871 -$912,789 -$906,038 -134.2% 01 Jul 2022 30 Sep 2022 10-Q 20 Nov 2023
Q2 2022 -$1,377,833 -$924,050 -$917,504 -140.2% 01 Apr 2022 30 Jun 2022 10-Q 20 Nov 2023
Q1 2022 -$460,329 -$375,380 -$369,659 -64.6% 01 Jan 2022 31 Mar 2022 10-Q 20 Nov 2023
Q4 2021 -$90,670 -$71,652 +$162,206 +69.4% 01 Oct 2021 31 Dec 2021 10-K 17 Apr 2023
Q3 2021 -$252,876 -$6,751 +$8,728 +56.4% 01 Jul 2021 30 Sep 2021 10-Q 04 Nov 2022
Q2 2021 -$261,604 -$6,546 +$16,386 +71.5% 01 Apr 2021 30 Jun 2021 10-Q 04 Nov 2022
Q1 2021 -$277,990 -$5,721 -$187,120 -1% 01 Jan 2021 31 Mar 2021 10-Q 04 Nov 2022
Q4 2020 -$90,870 -$233,858 -$291,781 -5% 01 Oct 2020 31 Dec 2020 10-K 15 Apr 2022
Q3 2020 $200,911 -$15,479 +$77,141 +83.3% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2022
Q2 2020 $123,770 -$22,932 +$457,356 +95.2% 01 Apr 2020 30 Jun 2020 10-Q 04 Nov 2022
Q1 2020 -$333,586 $181,399 +$861,308 01 Jan 2020 31 Mar 2020 10-Q 04 Nov 2022
Q4 2019 -$1,194,894 $57,923 -$310,538 -84.3% 01 Oct 2019 31 Dec 2019 10-K 15 Apr 2022
Q3 2019 -$884,356 -$92,620 +$557,258 +85.7% 01 Jul 2019 30 Sep 2019 10-Q 31 Jan 2020
Q2 2019 -$1,441,614 -$480,288 +$109,875 +18.6% 01 Apr 2019 30 Jun 2019 10-Q 31 Jan 2020
Q1 2019 -$1,551,489 -$679,909 -$9,662 -1.4% 01 Jan 2019 31 Mar 2019 10-Q 31 Jan 2020
Q4 2018 -$1,541,827 $368,461 +$8,365,612 01 Oct 2018 31 Dec 2018 10-K 16 Apr 2019
Q3 2018 -$9,907,439 -$649,878 +$727,021 +52.8% 01 Jul 2018 30 Sep 2018 10-Q 31 Jan 2020
Q2 2018 -$10,634,460 -$590,163 +$3,321,898 +84.9% 01 Apr 2018 30 Jun 2018 10-Q 31 Jan 2020
Q1 2018 -$13,956,358 -$670,247 +$1,022,353 +60.4% 01 Jan 2018 31 Mar 2018 10-Q 31 Jan 2020
Q4 2017 -$14,978,711 -$7,997,151 01 Oct 2017 31 Dec 2017 10-K 16 Apr 2019
Q3 2017 -$1,376,899 +$539,774 +28.2% 01 Jul 2017 30 Sep 2017 10-Q 16 Nov 2018
Q2 2017 -$3,912,061 -$2,617,218 -2% 01 Apr 2017 30 Jun 2017 10-Q 13 Aug 2018
Q1 2017 -$1,692,600 +$3,178,163 +65.2% 01 Jan 2017 31 Mar 2017 10-Q 14 May 2018
Q3 2016 -$50,298,163 -$1,916,673 +$11,912,314 +86.1% 01 Jul 2016 30 Sep 2016 10-Q 13 Nov 2017
Q2 2016 -$62,210,477 -$1,294,843 -$424,605 -48.8% 05 May 2016 30 Jun 2016 10-Q 14 Aug 2017
Q1 2016 -$61,785,872 -$4,870,763 -$8,977,764 -2.2% 01 Jan 2016 31 Mar 2016 10-Q 24 Oct 2016
Q4 2015 -$52,808,108 -$42,215,884 -$45,071,746 -15.8% 01 Oct 2015 31 Dec 2015 10-K 24 Oct 2016
Q3 2015 -$7,736,362 -$13,828,987 -$9,043,404 -1.9% 01 Jul 2015 30 Sep 2015 10-Q 13 Nov 2015
Q2 2015 $1,307,042 -$870,238 +$10,450,400 +92.3% 01 Apr 2015 30 Jun 2015 10-Q 13 Aug 2015
Q1 2015 -$9,143,358 $4,107,001 +$9,739,914 01 Jan 2015 31 Mar 2015 10-Q 24 Oct 2016
Q4 2014 -$18,883,272 $2,855,862 +$7,753,854 01 Oct 2014 31 Dec 2014 10-K 24 Oct 2016
Q3 2014 -$26,637,126 -$4,785,583 +$189,566 +3.8% 01 Jul 2014 30 Sep 2014 10-Q 13 Nov 2015
Q2 2014 -$26,826,692 -$11,320,638 -$6,283,988 -1.2% 01 Apr 2014 30 Jun 2014 10-Q 13 Aug 2015
Q1 2014 -$20,542,704 -$5,632,913 -$294,344 -5.5% 01 Jan 2014 31 Mar 2014 10-Q 14 May 2015
Q4 2013 -$20,248,360 -$4,897,992 -$1,064,325 -27.8% 01 Oct 2013 31 Dec 2013 10-K 31 Mar 2015
Q3 2013 -$19,184,035 -$4,975,149 -$1,190,226 -31.4% 01 Jul 2013 30 Sep 2013 10-Q 12 Nov 2013
Q2 2013 -$17,993,809 -$5,036,650 +$2,419,173 +32.4% 01 Apr 2013 30 Jun 2013 10-Q 08 Aug 2013
Q1 2013 -$20,412,982 -$5,338,569 -$614,924 -13% 01 Jan 2013 31 Mar 2013 10-Q 15 May 2014
Q4 2012 -$19,798,058 -$3,833,667 -$4,731,086 -5.3% 01 Oct 2012 31 Dec 2012 10-K 31 Mar 2014
Q3 2012 -$15,066,972 -$3,784,923 -$1,578,570 -71.5% 01 Jul 2012 30 Sep 2012 10-Q 12 Nov 2013
Q2 2012 -$13,488,402 -$7,455,823 -$6,664,462 -8.4% 01 Apr 2012 30 Jun 2012 10-Q 08 Aug 2013
Q1 2012 -$6,823,940 -$4,723,645 -$3,313,425 -2.3% 01 Jan 2012 31 Mar 2012 10-Q 09 May 2013
Q4 2011 -$3,510,515 $897,419 01 Oct 2011 31 Dec 2011 10-K 18 Mar 2013
Q3 2011 -$2,206,353 -$791,332 -55.9% 01 Jul 2011 30 Sep 2011 10-Q 14 Nov 2012
Q2 2011 -$791,361 +$1,465,998 +64.9% 01 Apr 2011 30 Jun 2011 10-Q 14 Aug 2012
Q1 2011 -$1,410,220 01 Jan 2011 31 Mar 2011 10-Q 15 May 2012
Q3 2010 -$1,415,021 01 Jul 2010 30 Sep 2010 10-Q 14 Nov 2011
Q2 2010 -$2,257,359 01 Apr 2010 30 Jun 2010 10-Q 15 Aug 2011

Nuo Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$2,323,705 +$847,731 +26.7% 01 Jan 2024 31 Dec 2024 10-K 01 Apr 2025
2023 -$3,171,436 +$300 +0.01% 01 Jan 2023 31 Dec 2023 10-K 01 Apr 2025
2022 -$3,171,736 -$3,081,066 -34% 01 Jan 2022 31 Dec 2022 10-K 19 Apr 2024
2021 -$90,670 +$200 +0.22% 01 Jan 2021 31 Dec 2021 10-K 17 Apr 2023
2020 -$90,870 +$1,104,024 +92.4% 01 Jan 2020 31 Dec 2020 10-K 15 Apr 2022
2019 -$1,194,894 +$346,933 +22.5% 01 Jan 2019 31 Dec 2019 10-K 15 Apr 2022
2018 -$1,541,827 +$13,436,884 +89.7% 01 Jan 2018 31 Dec 2018 10-K 16 Apr 2019
2017 -$14,978,711 01 Jan 2017 31 Dec 2017 10-K 16 Apr 2019
2015 -$52,808,108 -$33,924,836 -1.8% 01 Jan 2015 31 Dec 2015 10-K 24 Oct 2016
2014 -$18,883,272 +$1,365,088 +6.7% 01 Jan 2014 31 Dec 2014 10-K 24 Oct 2016
2013 -$20,248,360 -$450,302 -2.3% 01 Jan 2013 31 Dec 2013 10-K 31 Mar 2015
2012 -$19,798,058 -$16,287,543 -4.6% 01 Jan 2012 31 Dec 2012 10-K 31 Mar 2014
2011 -$3,510,515 +$3,306,236 +48.5% 01 Jan 2011 31 Dec 2011 10-K 18 Mar 2013
2010 -$6,816,751 01 Jan 2010 31 Dec 2010 10-K 29 Mar 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.